SynOx Therapeutics secures up to $35m debt financing with Hercules Capital to progress development and commercialisation of emactuzumab
- SynOx is developing emactuzumab – a potential best-in-class, next-generation CSF1(R) inhibiting monoclonal antibody
- Provides flexible loan facility to support additional clinical work and activities to drive its successful registration and commercialisation
- Funding is additional to recent $75m Series B financing
Dublin, Ireland and Oxford, UK, 30 April 2024: SynOx Therapeutics Limited (“SynOx” or the “Company”), the late-stage clinical biopharmaceutical company developing emactuzumab for the treatment of Tenosynovial Giant Cell Tumour (TGCT) and other diseases, today announces it has entered into a $35m loan facility with Hercules Capital, Inc. (NYSE:HTGC) (“Hercules”).
